Airway Disease Treatment Market expected to reach USD 3.54 billion by 2032

From GlobeNewswire: 2024-11-27 09:00:00

The Airway Disease Treatment Market was valued at USD 2.23 Billion in 2023 and is projected to reach USD 3.54 Billion by 2032, with a CAGR of 5.29%. High mortality rates in the US from COPD are driving demand for better therapies, leading to innovations in biologics and personalized medicine. Emerging markets and advancements in AI-driven diagnostics are expected to accelerate market growth globally.

The Asthma Segment dominated the market with a revenue share of 54% in 2023, driven by high disease prevalence and effective treatments. The COPD Segment is expected to grow at a CAGR of 6.16% from 2024-2032 due to an aging population and increased smoking-related diseases. Hospitals lead the market with a 43% revenue share, while clinics are expected to grow at a CAGR of 7.03% from 2024-2032.

North America dominated the market in 2023 with a 42% revenue share, driven by high healthcare expenditure and advanced medical infrastructure. Asia Pacific is set for rapid growth at a CAGR of 7.40% from 2024-2032, fueled by increased access to healthcare and rising respiratory disease prevalence. The market is expected to witness significant growth globally due to these factors. Significant investment and local innovations are driving growth in the Airway Disease Treatment Market, transforming the global competitive landscape. Boehringer Ingelheim introduced a new treatment in Qatar for interstitial lung diseases, while AstraZeneca presented advancements in therapies for respiratory diseases. The market report includes statistical insights, competitive landscape analysis, and regional segmentation. Contact S&S Insider for deeper insights.



Read more at GlobeNewswire: Airway Disease Treatment Market to Hit USD 3.54 Billion by